甘草酸二铵肠溶胶囊防治抗结核药物性肝损害的临床观察

The clinical observation on the effects of diammonium glycyrrhizinate enteric-coated capsules in preventing and treating liver damage caused by anti-tuberculosis drugs

目的观察甘草酸二铵肠溶胶囊对抗结核药物所致肝损害的防治效果。方法对初治肺结核216例,给予2HRZE/4HR(10HR)方案抗结核治疗,治疗组112例,全程加服甘草酸二铵肠溶胶囊;对照组104例,全程加服葡醛内酯片。结果治疗组出现肝损害12例(10.7%),其中HBsAg阳性患者出现肝损害8例(21.1%);对照组出现肝损害36例(34.6%),其中HBsAg阳性患者出现肝损害22例(68.8%)。两组差异显著(P<0.01)。HBsAg、HBeAg阳性患者在抗结核治疗中肝功能更易受到损害。结论甘草酸二铵肠溶胶囊在防治抗结核药物所致肝损害的发生是有效的,尤其是HBsAg阳性的结核病患者。

Objective To determine the effect of diammonium glycyrrhizinate enteric - coated capsules in preventing and treating liver caused by anti - tuberculosis drugs. Methods Two hundred and sixteen initially - treated pulmonary tuberculosis patients who received the regimen of 2HRZE/4HR（ 10HS）were randomly divided into 2 groups： Observe group, 12 cases,supplemented with diammonium glycyrrhizinate enteric -coated capsules for 3 years and Control group,104 cases,received glucurolactonel Results There were 12 cases who had liver damage in observe group （10.7%） ,in which HBsAg- positive liver damage in patients with 8 cases （21.1%） ;There were 36 cases who had liver damage in controi group（34.6% ） ,in which HBsAg -positive patients 22 cases of liver damage （68.8%）. There was Significant difference between the two groups（P 〈0.01 ）. HB＇sAg, HBeAg - positive patients were more likely to have liver damage in anti - tuberculosis therapy： Conclusions Diammonium glycyrrhizinate entericcoated capsules is effective in preventing and treating liver damage caused by anti - TB drugs, especially in patients with HBsAg - positive tuberCulOsis.